@CKD_ce Profile picture
Apr 12, 2022 55 tweets 41 min read Twitter logo Read on Twitter
1) Welcome to a new #accredited #tweetorial on Cardiorenal Disease in T2D & the Impact of Blocking the MR in Patients w/DKD, another CE/#CME program by one of the @GoggleDocs, this time our friend @AmarPut, Diabetes & Endocrine Consultant in the West Midlands 🇬🇧. #CaReMe #FOAMed Image
2) This program is supported by an educational grant from Bayer & is intended for #healthcare providers. Author disclosures can be found at ckd-ce.com/disclosures/. Prior programs, still available for CE/#CME credit, are at ckd-ce.com. CE/#CME credit 🇬🇧🇪🇺🇨🇦🇺🇸
3) So first – the ‘triple threat’ . . . We know of the link between the 🫀 and the kidneys and the ‘#cardiorenal’ syndrome, but what about in the setting of #diabetes?
4) Diabetes is a well known independent risk factor for #cardiovascular and #renal disease with recent #CVOTs highlighting this link.
5) Given the newer data we have especially from trials such as #EMPEROR reduced and preserved, &#CREDENCE, #DAPA CKD/HF, there appears to be relevance to looking at this dual pathology in the setting of type 2 diabetes management…
6) ADA/EASD @AmDiabetesAssn / @EASDelearning and many other #Guidelines mention the importance of #riskreduction for #CVD and renal separately in DM but do not mention a ‘cardiorenal’ entity separately in management Image
7) Perhaps this and multimorbidity might be something to explore in future guidance 🤔…but that is for another time!
A question: Approximately what percentage of patients in the 🇺🇸with #T2DM have #CKD?
8) Data from the 🇬🇧and the 🇺🇸show that about 20% - 40% of patients with diabetes develop #CKD. (US data below, from 🔓pubmed.ncbi.nlm.nih.gov/24990184/) Image
9) Another question…what is the prevalence of #CVD in patients with #T2DM globally 🌎?
10) Cardiovascular disease (#CVD) is a leading cause of morbidity and mortality in T2DM. It has an overall prevalence of 32.2%, and is responsible for about 50% deaths globally. See 🔓pubmed.ncbi.nlm.nih.gov/29884191/ Image
11) CVD risk in a person w/diabetes is ⬆️by the presence of #CKD & #uACR excretion has been associated with ⬆️CV risk.
It has also been suggested that endothelial dysfunction in diabetes may ➡️development and progression of renal and cardiac pathologies.
12) This appears to cause intractable changes in volume regulation, sodium homeostasis, inflammation, & metabolism that lead to cardiorenal disease and mortality. 🔓frontiersin.org/articles/10.33…
13) But what about the combined comorbidity?
This study (🔓pubmed.ncbi.nlm.nih.gov/28089648/) looked at the prevalence of CKD in pts w/diabetes with (& without) CVD, noting the higher likelihood of CKD in the presence of CVD (with a strong prevalence of type 2 cardiorenal syndrome). Image
14) In a cohort of people with new onset #HF, hospitalisation and mortality was higher in patients with T2D or CKD, and worst in those with both comorbidities. See 🔓thelancet.com/journals/eclin…
@kamleshkhunti @profmjdavies @scelee1 @LDC_tweets Image
15) But what about presence of #T2DM in pts w/#cardiorenal syndrome? Read on…
In a study of pts admitted with cardiorenal syndrome, those w/CRS had a higher prevalence (2/3rds patients) of diabetes, mostly T2DM, & high 1-yr mortality. 🔓pubmed.ncbi.nlm.nih.gov/32912147/
16) Though we focus on #T2DM, there have been data also looking at those with #T1DM
So… is the risk of #cardiorenal disease at younger ages higher in those with type 1 or type 2 DM?
17) Adult patients with T1D vs T2D had an overall greater risk of cardiorenal disease (#HF and #CKD) across all ages, MI and all-cause death at middle-older ages, and stroke at younger ages. Sobering! Image
18) Total age-adjusted #CVRD burden & risks were greater among those with #T1D compared with #T2D (🔓pubmed.ncbi.nlm.nih.gov/33653822/) Image
19) This suggests that there is indeed a role for assessment for cardiorenal disease in those with T2D of course individually, but actually as combined co-morbidities to aid management of this triple threat!
And what of the management…
20) Slightly beyond the scope of this tweetorial but a few tantalizing considerations…
Looking at the mechanisms of #GLP-1 RAs we could see how they might be beneficial in those with #cardiorenal disease … (🔓doi.org/10.17925/USE.2…) Image
21) But it's in the #SGLT2i area where we get stronger support for use in CRS…
(and 👏@Sglt2inhibitorL @GoggleDocs @RpratleyMD @AliceYYCheng @drricardocorrea @edgarvlermamd @nephondemand ) Image
22) Kalra et al (ref in tweet 21) suggest a potential mode of action for their benefit: Image
23) There is even suggestion of when to use #SGLT2 depending on #CRS type… Image
24) Interesting thoughts and considerations, it remains to be seen if this is likely to occur clinically…what do you think? Comment below . . . and return TOMORROW for more education on #cardiorenal syndrome and #diabetes!
25) Welcome back! You're on a @GoggleDocs-led tour of #cardiorenal syndrome and #DKD. We'll be talking about #MRAs too as YOU earn🆓CE/#CME: 0.75h credit for #physicians #physicianassociates #nurses #NPs #pharmacists 🇺🇸🇬🇧🇨🇦🇪🇺!
26) So we left off yesterday (scroll ⤴️) talking about the potential role for #SGTL2i in the management of #CRS with #diabetes.
Now…something that definitely is in practice…#mineralocorticoid antagonism in #DKD!
27) We are intentionally not covering finerenone as this has been well covered by fellow @GoggleDocs member @drkevinfernando (earn credit still at ckd-ce.com/mra1/).
But . . .
28) It's important to know that in #DKD, overactivation of #MR has been implicated as a driver of inflammation and fibrosis.
Local activation of #RAAS has been shown to contribute to DKD (see 🔓frontiersin.org/articles/10.33…) Image
29) #MRAs have been suggested as an option in DKD management through potential mechanistic reasons (🔓academic.oup.com/ndt/advance-ar… and accompanying 🆓📽️highlights at academic.oup.com/ndt/pages/auth… ) Image
30) And as per our friends at @goKDIGO, ACE/ARBs have long been and remain the staple medication of CKD/DKD management Image
31) However, long-term administration of ACE/ARBs paradoxically⬆️aldosterone levels (aldosterone breakthrough) - thereby suggesting MRAs may be of benefit…but this increases the risk of hyperkalaemia (and yes you can earn MORE🆓credit on hyperK mgt at cardiometabolic-ce.com/category/hyper…)…
32) Studies of medications in addition to ACE/ARBs have also highlighted this with the well-known #ALTITUDE study looking at #aliskrein as add on to ACEi/ARB stopped early with the risk of hyperkalaemia notable (🔓nejm.org/doi/full/10.10…) Image
33) ... though a 2015 paper (🔓pubmed.ncbi.nlm.nih.gov/25220494/) reviewing studies with a total over 500 patients suggests that overall it may not be that high…🤔 Image
34) Since #spironolactone has the longest history of all the MRAs, MRA-in-DKD studies were performed with it. 1st report of proteinuria⬇️from spironolactone as an add-on therapy to a RAS inhibitor in patients with CKD (5 of 8 had DKD) was in 2001 (nejm.org/doi/10.1056/NE…): Image
35) The first small, double-blinded, controlled, 2-period crossover study was performed by K. Rossing et al, 🔓doi.org/10.2337/diacar….
36) 21 patients w/T2DM on RAASi were treated w/spironolactone 25mg or placebo x 8wks ➡️ significant ⬇️ in albuminuria (& BP)….with minimal hyperkalaemia in this case…however…
This metanalysis of spironolactone shows reductions in uACR with no significant change in eGFR… Image
37) But …the risk of hyperkalaemia was noted…
🔓doi.org/10.1016/j.clin… Image
38) What about the other well known (second-generation) steroidal MRA…#eplerenone?
39) Alas, not much data here, but we do have… 🔓cjasn.asnjournals.org/content/1/5/940: 268 pts w/T2D+albuminuria (UACR 50 mg/g), open-label run-in with enalapril 20 mg OD then.. 12wk tx w/eplerenone 50 mg v 100 mg v placebo.
Notable changes in uACR with less eGFR decline were promising ImageImageImage
40) Even more so this finding that hyperkalaemia may not be as significant… Image
41) ... though one study is not strong enough to reassure, with the the risk of hyperkalaemia still a caution. accessdata.fda.gov/drugsatfda_doc…
42) So TOMORROW we'll look at the whole field of #MRAs in general . . . AND provide your super secret (not really) link to your🆓CE/#CME, all delivered RIGHT HERE on Twitter and @ckd_ce! Be sure to COME BACK!
@HecmagsMD @ChristosArgyrop @nephondemand @edgarvlermamd @kdpsinghlab
43) WELCOME BACK! You are some great @GoggleDocs-led learning and just a few🖱️clicks away from FREE CE/#CME! We're wrapping up this discussion of #cardiorenal disease, #DKD, and #MRAs.
@drpatrickholmes @HannahBeba @dguerrot @RpratleyMD @AgarwalRajivMD @MasriAhmadMD @cpcannon
44) Let’s broaden the field to look at MRAs in general… this analysis of MRAs also noted benefits seen with individual therapies: 🔓onlinelibrary.wiley.com/doi/10.1111/jd…
45) Effect on #eGFR Image
46) Effect on #uACR excretion Image
47) Change in #bloodpressure (c = SBP, d = DBP) Image
48) Yet the same hyperkalaemia risk remains... ⚠️ Image
49) Coming full circle🔄…what about MRAs in pts w/cardiorenal disease in the setting of #diabetes?
The answer: Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease 🔓ahajournals.org/doi/10.1161/JA… ImageImage
50) Again, potential benefit in mortality reduction but notable increase in hospitalization for #hyperkalaemia!
MRAs have a role in DKD in⬇️albuminuria. Hard outcomes such as kidney disease progression, cardiovascular events and mortality data are not so clear for earlier MRAs
51) However, the use of steroidal MRA in #DKD has been limited by its side effects, especially hyperkalemia.
52) Use in this setting would require diet review, ACE inhibitor/ARB use monitoring, possible potassium binder use, regular serum potassium and renal function monitoring….maybe highlighting where a non-steroidal MRA may have its benefits…😊
53) So what do you think? What is the main concern with use of MRAs in those with diabetes?
54) Bet you got it right. Diabetes or not, hyperkaelemia if your biggest concern with #MRA therapy! Don't miss the opportunity for more education and CE/#CME credit on management of #hyperkalemia at cardiometabolic-ce.com/category/hyper…
55) And there you have it! Congratulations on completing your epic journey through #cardiorenal disease to MRAs in #DKD! Go forth & claim your 0.75h credit 🇬🇧🇨🇦🇪🇺🇺🇸at ckd-ce.com/mra3/! This is your friendly twitterhood GoggleDoc signing off! FOLLOW US for more education!

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with @CKD_ce

@CKD_ce Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ckd_ce

Feb 21
1) Welcome to this #accredited #tweetorial on genetic testing in the evaluation of patients with cystic kidney disease. #Kidney #cysts are a frequent finding, ranging from simple cysts to suspected or confirmed #ADPKD.
Expert author @dguerrot of @CHURouen 🇫🇷 leads us!
2) This program is supported by an educational grant from Otsuka Pharmaceuticals & is intended for #HCPs. #Physicians #Physicianassociates #nurses #nursepractioners #pharmacists 🇺🇸🇨🇦🇪🇺🇬🇧 earn CE/#CME credit. Statement of accreditation & faculty disclosures ckd-ce.com/disclosures
3a) Fortuitous discovery of non-malignant kidney cysts is increasingly frequent with age, and often leads to #nephrology referral.
Read 52 tweets
Jan 3
1) Welcome to our #accredited #tweetorial on clinical trial results and emerging data for treatment of Diabetes and CKD #DM in #CKD. I am Brian Rifkin MD, @brian_rifkin, from the Hattiesburg Clinic. #Nephtwitter #Medtwitter #FOAMed
2) This #accredited #tweetorial series on #kidneydisease #CKD is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance. It is not intended for US- or UK-based HCPs. Accreditation statement & faculty disclosures at ckd-ce.com/disclosures/.
3) This activity is accredited for #physicians #physicianassociates #nurses #NPs #pharmacists. Prior programs in this series, still eligible for CE/#CME, can be accessed at ckd-ce.com. FOLLOW US to learn from expert faculty!
Read 41 tweets
Oct 18, 2022
1) Welcome to this new #accredited #tweetorial on “Strategies to Apply Current Clinical Trial Data for SGLT2i to Reduce the Progression of CKD,” authored by our ⭐️tweetorialist Edgar V. Lerma 🇵🇭 @edgarvlermamd Image
2) This program is #accredited for CE/#CME #physicians #physicianassociates #nurses #pharmacists #nursepractitioners & is supported by an educational grant from the Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company. It is intended for healthcare professionals.
3) Faculty disclosures and statement of accreditation are provided at ckd-ce.com/disclosures/. Please FOLLOW @ckd_ce (& @cardiomet_CE!) so you don't miss ANY of our unique serialized #tweetorials, always 🆓, always from expert authors! Prior programs at ckd-ce.com/category/dkd/ .
Read 26 tweets
Sep 13, 2022
1) Welcome to a new #accredited (0.75h CE/#CME) #tweetorial on challenging case presentations for pts with #cardiometabolic disease, #CaReMe #FOAMed.
Our expert author is Claire Davies. @claireyrivs is a specialist diabetes & endocrinology #pharmacist working in Gateshead in 🇬🇧. Image
2) She is a member of UKCPA Diabetes & Endocrinology committee @UKCPADiabetes & works across #diabetes, #endocrinology, & emergency/acute care in Secondary Care. She is currently involved in development of regional guidelines & education to support medicines optimisation for PLWD
3a) This program is intended for healthcare professionals and is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly Company.
Read 36 tweets
Sep 7, 2022
1) Welcome to our new #accredited #tweetorial on the Pathophysiology of #DKD in #T2D: Traditional Teaching and New Insights. Our expert author is Hans-Joachim Anders, MD, @hjanders_hans from @LMU_Uniklinikum of @LMU_Muenchen
2) This #accredited #tweetorial series on the foundations of #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.
3) This activity is accredited for #physicians #physicianassociates #nurses #NPs #pharmacists. Past programs still eligible for credit can be found at ckd-ce.com. Faculty disclosures & accreditation statement are at ckd-ce.com/disclosures/. FOLLOW US!
Read 48 tweets
Aug 23, 2022
1a) Welcome to one of our favorite events on the @academiccme #accredited #tweetorial feeds: a takeover of our programming from @GoggleDocs! The focus of this tweetorial is data from #ADA2022 on #SGLT2i beyond cardiac disease. Our expert author is @GoggleDocs' @drpatrickholmes. Image
1b) Check out our other #ADA2022 recap #tweetorial by new @GoggleDocs family member @Ines_VFonseca who focused on the cardiac data presented: ckd-ce.com/dkd13_ada22a/
2) This program is #accredited for CE/#CME #physicians #physicianassociates #nurses #pharmacists #nursepractitioners & is supported by an educational grant from the Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company. It is intended for healthcare professionals.
Read 59 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!


0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy


3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!